Clinical Trials
13 trialsNCT00660218 2021-11-08
A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer
State University of New York - Upstate Medical University
Phase 1/2 Completed
NCT00522795 2020-02-17
Neoadjuvant Paclitaxel Poliglumex, Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial (CTI#X64001)
Brown University
Phase 2 Completed
NCT01402063 2020-02-17
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation
Brown University
Phase 2 Completed
NCT00045682 2017-07-13
CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT00265733 2016-12-06
Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00446836 2016-03-17
Efficacy and Safety Study of Xyotax to Treat Prostate Cancer
The Methodist Hospital Research Institute
Phase 2 Completed
NCT00060359 2015-05-08
Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
GOG Foundation
Phase 1 Completed
NCT00598247 2014-02-06
A Pilot Study of PPX in Women With Metastatic Colorectal Cancer
University of Southern California
Phase 1 Completed
NCT00487669 2014-01-09
Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC)
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT00017017 2013-05-30
CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00270907 2013-02-13
CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00069901 2008-09-22
Phase II CT-2103/Carboplatin in Ovarian Cancer
CTI BioPharma
Phase 2 Completed
NCT00148707 2007-12-21
Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed